Israel Englander Millennium Management
Israel “Izzy” Englander is the founder of Millennium Management, one of the world’s largest multi-strategy hedge fund platforms. Millennium allocates capital across hundreds of independent teams rather than a single house view, with rigorous risk controls at the platform level. Englander’s model has been highly influential in the rise of pod-shop multi-manager structures across the industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$643M |
| 2 |
AT&T
T
|
+$311M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$306M |
| 4 |
Microsoft
MSFT
|
+$292M |
| 5 |
Ametek
AME
|
+$215M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$887M |
| 2 |
Apple
AAPL
|
+$694M |
| 3 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$616M |
| 4 |
Amazon
AMZN
|
+$596M |
| 5 |
Linde
LIN
|
+$531M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 58.05% |
| 2 | Technology | 7.69% |
| 3 | Financials | 6.83% |
| 4 | Healthcare | 6.42% |
| 5 | Industrials | 4.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4676
Banco Santander
SAN
$213B
| $971K | ﹤0.01% |
268,141
-1,414,702
| -84% | -$5.22M |
|
4677
Lyell Immunopharma
LYEL
$356M
| $970K | ﹤0.01% |
3,276
-3,282
| -50% | -$983K |
|
|
STR
4678
DELISTED
Sitio Royalties
STR
| $970K | ﹤0.01% |
51,611
+6,678
| +15% | +$125K |
|
4679
Ternium
TX
$10.8B
| $970K | ﹤0.01% |
22,936
-585,814
| -96% | -$28.6M |
|
|
CASI
4680
DELISTED
CASI Pharmaceuticals
CASI
| $969K | ﹤0.01% |
81,411
-29,810
| -27% | -$403K |
|
4681
Tompkins Financial
TMP
$1.41B
| $969K | ﹤0.01% |
11,972
+4,801
| +67% | +$372K |
|
|
HLLY.WS
4682
CALL
DELISTED
Holley Inc Warrants
HLLY.WS
| $967K | ﹤0.01% |
+333,333
| New | +$890K |
|
|
VGR
4683
DELISTED
Vector Group Ltd.
VGR
| $967K | ﹤0.01% |
+106,991
| New | +$1.04M |
|
4684
PRA Group
PRAA
$721M
| $964K | ﹤0.01% |
22,877
+6,002
| +36% | +$239K |
|
4685
iShares MSCI Philippines ETF
EPHE
$150M
| $962K | ﹤0.01% |
32,346
+6,419
| +25% | +$190K |
|
|
AWH
4686
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
| $961K | ﹤0.01% |
19,720
-4,387
| -18% | -$271K |
|
4687
Karooooo
KARO
$2.08B
| $960K | ﹤0.01% |
32,517
-2,071
| -6% | -$70.7K |
|
4688
Orchestra BioMed
OBIO
$311M
| $960K | ﹤0.01% |
97,030
+34,004
| +54% | +$336K |
|
|
NAGE
4689
Niagen Bioscience
NAGE
$260M
| $960K | ﹤0.01% |
153,068
+50,850
| +50% | +$419K |
|
|
MMV
4690
DELISTED
MultiMetaVerse Holdings Limited Class A Ordinary Share
MMV
| $960K | ﹤0.01% |
96,171
+78,648
| +449% | +$779K |
|
|
RMAX
4691
DELISTED
RE/MAX Holdings
RMAX
| $959K | ﹤0.01% |
30,792
-24,056
| -44% | -$799K |
|
|
CRHC
4692
CALL
DELISTED
Cohn Robbins Holdings Corp.
CRHC
| $959K | ﹤0.01% |
1,059,203
-88,231
| -8% | -$866K |
|
4693
Universal Corp
UVV
$1.14B
| $958K | ﹤0.01% |
19,831
+7,897
| +66% | +$401K |
|
4694
PUT
TJX Companies
TJX
$149B
| $957K | ﹤0.01% |
+14,500
| New | +$1.01M |
|
|
ACTDU
4695
DELISTED
ArcLight Clean Transition Corp. II Unit
ACTDU
| $957K | ﹤0.01% |
96,459
-315,220
| -77% | -$3.14M |
|
4696
Peoples Bancorp
PEBO
$1.43B
| $956K | ﹤0.01% |
30,235
-14,555
| -32% | -$440K |
|
4697
Carlyle Secured Lending
CGBD
$811M
| $953K | ﹤0.01% |
71,067
+33,864
| +91% | +$462K |
|
4698
CALL
Deutsche Bank
DB
$75.8B
| $953K | ﹤0.01% |
+75,000
| New | +$940K |
|
|
BITE
4699
DELISTED
Bite Acquisition Corp.
BITE
| $953K | ﹤0.01% |
97,988
+60,759
| +163% | +$588K |
|
|
APR
4700
DELISTED
Apria, Inc. Common Stock
APR
| $952K | ﹤0.01% |
25,625
-237,075
| -90% | -$7.8M |
|
Similar funds
Israel Englander's Q3 2021 Portfolio in Review
As of Q3 2021, Israel Englander held 7,698 positions worth $167B, up 2.3% from $163B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Israel Englander's Q3 2021 filing shows 1,245 new, 2,719 increased, 2,446 reduced and 981 closed positions. Its largest new stake was Sight Sciences: 1,577,092 shares worth $35.8M. The largest sale was Alexion Pharmaceuticals, an estimated $887M.
By sector, the portfolio is most concentrated in Miscellaneous at 58% of assets, up from 55% a quarter earlier, followed by Technology and Financials.
- Israel Englander's largest Q3 2021 buy was Sight Sciences: 1,577,092 shares worth $35.8M.
- Israel Englander added most to State Street SPDR S&P 500 ETF Trust in Q3 2021, an estimated $643M increase.
- Israel Englander's biggest Q3 2021 reduction was Apple, cutting an estimated $694M.
- Israel Englander fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $887M.
- Israel Englander's ten largest holdings make up 18% of its $167B portfolio in Q3 2021.
- Israel Englander opened 1,245 new positions and closed 981 in Q3 2021.
- Israel Englander's portfolio value rose 2.3% quarter-over-quarter to $167B.
Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.